{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,30]],"date-time":"2026-06-30T20:51:08Z","timestamp":1782852668091,"version":"3.54.5"},"reference-count":27,"publisher":"e-Century Publishing Corporation","issue":"12","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Am J Transl Res"],"DOI":"10.62347\/rknh8649","type":"journal-article","created":{"date-parts":[[2024,12,31]],"date-time":"2024-12-31T01:21:52Z","timestamp":1735608112000},"page":"7591-7599","source":"Crossref","is-referenced-by-count":1,"title":["Clinical effectiveness of entecavir versus tenofovir disoproxil fumarate tablets in chronic hepatitis B treatment"],"prefix":"10.62347","volume":"16","author":[{"given":"You","family":"Zhou","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"48694","published-online":{"date-parts":[[2024]]},"reference":[{"key":"ref0","doi-asserted-by":"publisher","first-page":"14980","DOI":"10.1038\/s41598-023-39582-9","article-title":"Modelling the dynamics of acute and chronic hepatitis B with optimal control","volume":"13","author":"Khan","year":"2023","unstructured":"Khan T, Rihan FA and Ahmad H. Modelling the dynamics of acute and chronic hepatitis B with optimal control. Sci Rep 2023; 13: 14980.","journal-title":"Sci Rep"},{"key":"ref1","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1111\/1348-0421.12943","article-title":"Detection of the serological markers hepatitis B virus surface antigen (HBsAg) and hepatitis B core IgM antibody (anti-HBcIgM) in the diagnosis of acute hepatitis B virus infection after recent exposure","volume":"66","author":"de Almeida Ponde","year":"2022","unstructured":"de Almeida Ponde RA. Detection of the serological markers hepatitis B virus surface antigen (HBsAg) and hepatitis B core IgM antibody (anti-HBcIgM) in the diagnosis of acute hepatitis B virus infection after recent exposure. Microbiol Immunol 2022; 66: 1-9.","journal-title":"Microbiol Immunol"},{"key":"ref2","doi-asserted-by":"publisher","first-page":"805318","DOI":"10.3389\/fphar.2021.805318","article-title":"Association between nonselective beta-blocker use and hepatocellular carcinoma in patients with chronic hepatitis B without cirrhosis and decompensation","volume":"12","author":"Cheng","year":"2022","unstructured":"Cheng HY, Lin HC, Lin HL, Uang YS, Keller JJ and Wang LH. Association between nonselective beta-blocker use and hepatocellular carcinoma in patients with chronic hepatitis B without cirrhosis and decompensation. Front Pharmacol 2022; 12: 805318.","journal-title":"Front Pharmacol"},{"key":"ref3","doi-asserted-by":"publisher","unstructured":"Campbell C, Wang T, Burrow R, Mandal S, Hippisley-Cox J, Barnes E and Matthews PC. Estimating the epidemiology of chronic Hepatitis B Virus (HBV) infection in the UK: what do we know and what are we missing? Wellcome Open Res 2023; 7: 203.","DOI":"10.12688\/wellcomeopenres.17941.2"},{"key":"ref4","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1016\/j.cld.2022.08.001","article-title":"Chronic hepatitis B virus and hepatitis D virus: new developments","volume":"27","author":"Robinson","year":"2023","unstructured":"Robinson A, Wong R and Gish RG. Chronic hepatitis B virus and hepatitis D virus: new developments. Clin Liver Dis 2023; 27: 17-25.","journal-title":"Clin Liver Dis"},{"key":"ref5","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1186\/s41687-021-00398-8","article-title":"Health-related quality of life for adults living with hepatitis B in the United States: a qualitative assessment","volume":"5","author":"Freeland","year":"2021","unstructured":"Freeland C, Racho R, Kamischke M, Moraras K, Wang E, Cohen C and Kendrick S. Health-related quality of life for adults living with hepatitis B in the United States: a qualitative assessment. J Patient Rep Outcomes 2021; 5: 121.","journal-title":"J Patient Rep Outcomes"},{"key":"ref6","unstructured":"Tsai E. Review of current and potential treatments for chronic hepatitis B virus infection. Gastroenterol Hepatol (N Y) 2021; 17: 367-376."},{"key":"ref7","doi-asserted-by":"publisher","first-page":"1403","DOI":"10.1002\/cmdc.202000849","article-title":"Advances in nucleoside and nucleotide analogues in tackling human immunodeficiency virus and hepatitis virus infections","volume":"16","author":"Ramesh","year":"2021","unstructured":"Ramesh D, Vijayakumar BG and Kannan T. Advances in nucleoside and nucleotide analogues in tackling human immunodeficiency virus and hepatitis virus infections. ChemMedChem 2021; 16: 1403-1419.","journal-title":"ChemMedChem"},{"key":"ref8","doi-asserted-by":"publisher","first-page":"1603","DOI":"10.3390\/ph16111603","article-title":"Entecavir: a review and considerations for its application in oncology","volume":"16","author":"Lourenco","year":"2023","unstructured":"Lourenco T and Vale N. Entecavir: a review and considerations for its application in oncology. Pharmaceuticals (Basel) 2023; 16: 1603.","journal-title":"Pharmaceuticals (Basel)"},{"key":"ref9","doi-asserted-by":"publisher","first-page":"1299","DOI":"10.1111\/apt.17438","article-title":"Entecavir versus tenofovir on prognosis of hepatitis B virus-related hepatocellular carcinoma after curative hepatectomy","volume":"57","author":"Kao","year":"2023","unstructured":"Kao WY, Tan EC, Lee HL, Huang YH, Huo TI, Chang CC, Chiou JF, Hou MC, Wu JC and Su CW. Entecavir versus tenofovir on prognosis of hepatitis B virus-related hepatocellular carcinoma after curative hepatectomy. Aliment Pharmacol Ther 2023; 57: 1299-1312.","journal-title":"Aliment Pharmacol Ther"},{"key":"ref10","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1159\/000519440","article-title":"Real-world single-center comparison of the safety and efficacy of entecavir, tenofovir disoproxil fumarate, and tenofovir alafenamide in patients with chronic hepatitis B","volume":"65","author":"Jeong","year":"2022","unstructured":"Jeong S, Shin HP and Kim HI. Real-world single-center comparison of the safety and efficacy of entecavir, tenofovir disoproxil fumarate, and tenofovir alafenamide in patients with chronic hepatitis B. Intervirology 2022; 65: 94-103.","journal-title":"Intervirology"},{"key":"ref11","doi-asserted-by":"publisher","unstructured":"Byun KS, Choi J, Kim JH, Lee YS, Lee HC, Kim YJ, Yoo BC, Kwon SY, Gwak GY and Lim YS. Tenofovir alafenamide for drug-resistant hepatitis B: a randomized trial for switching from tenofovir disoproxil fumarate. Clin Gastroenterol Hepatol 2022; 20: 427-437, e425.","DOI":"10.1016\/j.cgh.2021.04.045"},{"key":"ref12","doi-asserted-by":"publisher","first-page":"1126","DOI":"10.3348\/kjr.2022.0822","article-title":"2022 KLCA-NCC Korea practice guidelines for the management of hepatocellular carcinoma","volume":"23","author":"Liver Cancer Association (KLCA)","year":"2022","unstructured":"Korean Liver Cancer Association (KLCA) and National Cancer Center (NCC) Korea. 2022 KLCA-NCC Korea practice guidelines for the management of hepatocellular carcinoma. Korean J Radiol 2022; 23: 1126-1240.","journal-title":"Korean J Radiol"},{"key":"ref13","doi-asserted-by":"publisher","first-page":"260","DOI":"10.1007\/s12072-019-09943-6","article-title":"Long-term efficacy and safety of tenofovir disoproxil fumarate in Chinese patients with chronic hepatitis B: 5-year results","volume":"13","author":"Liang","year":"2019","unstructured":"Liang X, Gao Z, Xie Q, Zhang J, Sheng J, Cheng J, Chen C, Mao Q, Zhao W, Ren H, Tan D, Niu J, Chen S, Pan C, Tang H, Wang H, Mao Y, Jia J, Ning Q, Xu M, Wu S, Li J, Zhang X, Zhang W, Xiong C and Hou J. Long-term efficacy and safety of tenofovir disoproxil fumarate in Chinese patients with chronic hepatitis B: 5-year results. Hepatol Int 2019; 13: 260-269.","journal-title":"Hepatol Int"},{"key":"ref14","doi-asserted-by":"publisher","first-page":"567","DOI":"10.1186\/s12879-021-06237-x","article-title":"Short-term and long-term safety and efficacy of tenofovir alafenamide, tenofovir disoproxil fumarate and entecavir treatment of acute-on-chronic liver failure associated with hepatitis B","volume":"21","author":"Li","year":"2021","unstructured":"Li J, Hu C, Chen Y, Zhang R, Fu S, Zhou M, Gao Z, Fu M, Yan T, Yang Y, Li J, Liu J, Chen T, Zhao Y and He Y. Short-term and long-term safety and efficacy of tenofovir alafenamide, tenofovir disoproxil fumarate and entecavir treatment of acute-on-chronic liver failure associated with hepatitis B. BMC Infect Dis 2021; 21: 567.","journal-title":"BMC Infect Dis"},{"key":"ref15","doi-asserted-by":"publisher","first-page":"1425","DOI":"10.14218\/jcth.2023.00320","article-title":"Guidelines for the prevention and treatment of chronic hepatitis B (version 2022)","volume":"11","author":"You","year":"2023","unstructured":"You H, Wang F, Li T, Xu X, Sun Y, Nan Y, Wang G, Hou J, Duan Z, Wei L, Jia J and Zhuang H; Chinese Society of Hepatology, Chinese Medical Association; Chinese Society of Infectious Diseases, Chinese Medical Association. Guidelines for the prevention and treatment of chronic hepatitis B (version 2022). J Clin Transl Hepatol 2023; 11: 1425-1442.","journal-title":"J Clin Transl Hepatol"},{"key":"ref16","doi-asserted-by":"publisher","unstructured":"Zhang M, Li Y, Fan Z, Shen D, Huang X, Yu Q, Liu M, Ren F, Wang X, Dai L, Wang P, Ye H, Shi J, Yang X, Zhang S and Zhang J. Assessing health-related quality of life and health utilities in patients with chronic hepatitis B-related diseases in China: a cross-sectional study. BMJ Open 2021; 11: e047475.","DOI":"10.1136\/bmjopen-2020-047475"},{"key":"ref17","doi-asserted-by":"publisher","first-page":"3793","DOI":"10.3748\/wjg.v28.i29.3793","article-title":"Epidemiologic and socioeconomic factors impacting hepatitis B virus and related hepatocellular carcinoma","volume":"28","author":"Gnyawali","year":"2022","unstructured":"Gnyawali B, Pusateri A, Nickerson A, Jalil S and Mumtaz K. Epidemiologic and socioeconomic factors impacting hepatitis B virus and related hepatocellular carcinoma. World J Gastroenterol 2022; 28: 3793-3802.","journal-title":"World J Gastroenterol"},{"key":"ref18","doi-asserted-by":"publisher","first-page":"975584","DOI":"10.3389\/fmicb.2022.975584","article-title":"Current treatment of chronic hepatitis B: clinical aspects and future directions","volume":"13","author":"Zhu","year":"2022","unstructured":"Zhu M, Wang H, Lou T, Xiong P, Zhang J, Li L, Sun Y and Wu Y. Current treatment of chronic hepatitis B: clinical aspects and future directions. Front Microbiol 2022; 13: 975584.","journal-title":"Front Microbiol"},{"key":"ref19","doi-asserted-by":"publisher","first-page":"821","DOI":"10.1002\/psp4.12955","article-title":"Population pharmacokinetics of tenofovir given as either tenofovir disoproxil fumarate or tenofovir alafenamide in an African population","volume":"12","author":"Kawuma","year":"2023","unstructured":"Kawuma AN, Wasmann RE, Sinxadi P, Sokhela SM, Chandiwana N, Venter WDF, Wiesner L, Maartens G and Denti P. Population pharmacokinetics of tenofovir given as either tenofovir disoproxil fumarate or tenofovir alafenamide in an African population. CPT Pharmacometrics Syst Pharmacol 2023; 12: 821-830.","journal-title":"CPT Pharmacometrics Syst Pharmacol"},{"key":"ref20","doi-asserted-by":"publisher","first-page":"1354","DOI":"10.3390\/v13071354","article-title":"Mathematical modelling of the molecular mechanisms of interaction of tenofovir with emtricitabine against HIV","volume":"13","author":"Iannuzzi","year":"2021","unstructured":"Iannuzzi S and von Kleist M. Mathematical modelling of the molecular mechanisms of interaction of tenofovir with emtricitabine against HIV. Viruses 2021; 13: 1354.","journal-title":"Viruses"},{"key":"ref21","doi-asserted-by":"publisher","first-page":"1521","DOI":"10.12688\/f1000research.128116.2","article-title":"Factors affecting HBV DNA suppression in chronic hepatitis B patients treated with tenofovir disoproxil fumarate","volume":"11","author":"Darmadi","year":"2023","unstructured":"Darmadi D, Lindarto D, Siregar J, Widyawati T, Rusda M, Amin MM, Yusuf F, Eyanoer PC, Lubis M and Rey I. Factors affecting HBV DNA suppression in chronic hepatitis B patients treated with tenofovir disoproxil fumarate. F1000Res 2023; 11: 1521.","journal-title":"F1000Res"},{"key":"ref22","doi-asserted-by":"publisher","unstructured":"Liu R, Qiao J, Zhang L and Dou Z. Therapeutic effectiveness analysis of tenofovir alafenamide and tenofovir disoproxil fumarate on the treatment for chronic hepatitis B. Medicine (Baltimore) 2024; 103: e37953.","DOI":"10.1097\/MD.0000000000037953"},{"key":"ref23","doi-asserted-by":"publisher","first-page":"2018","DOI":"10.1002\/hep.25818","article-title":"Randomized, placebo-controlled trial of tenofovir disoproxil fumarate in adolescents with chronic hepatitis B","volume":"56","author":"Murray","year":"2012","unstructured":"Murray KF, Szenborn L, Wysocki J, Rossi S, Corsa AC, Dinh P, McHutchison J, Pang PS, Luminos LM, Pawlowska M and Mizerski J. Randomized, placebo-controlled trial of tenofovir disoproxil fumarate in adolescents with chronic hepatitis B. Hepatology 2012; 56: 2018-2026.","journal-title":"Hepatology"},{"key":"ref24","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1007\/s00535-022-01855-x","article-title":"entecavir on prognosis of hepatitis B virus-related hepatocellular carcinoma after curative resection","volume":"57","author":"Wang","year":"2022","unstructured":"Wang XH, Hu ZL, Fu YZ, Hou JY, Li WX, Zhang YJ, Xu L, Zhou QF, Chen MS and Zhou ZG. Tenofovir vs. entecavir on prognosis of hepatitis B virus-related hepatocellular carcinoma after curative resection. J Gastroenterol 2022; 57: 185-198.","journal-title":"J Gastroenterol"},{"key":"ref25","doi-asserted-by":"publisher","first-page":"212","DOI":"10.1097\/MEG.0000000000002476","article-title":"Efficacy and safety of long-term postpartum antiviral therapy in hepatitis B virus-infected mothers receiving prophylactic tenofovir disoproxil fumarate treatment","volume":"35","author":"Feng","year":"2023","unstructured":"Feng Y, Yao N, Shi L, Zhu Y, Liu J, He Y, Zhao Y and Chen T. Efficacy and safety of long-term postpartum antiviral therapy in hepatitis B virus-infected mothers receiving prophylactic tenofovir disoproxil fumarate treatment. Eur J Gastroenterol Hepatol 2023; 35: 212-218.","journal-title":"Eur J Gastroenterol Hepatol"},{"key":"ref26","doi-asserted-by":"publisher","first-page":"335","DOI":"10.14218\/jcth.2020.00164","article-title":"Tenofovir alafenamide fumarate, tenofovir disoproxil fumarate and entecavir: which is the most effective drug for chronic hepatitis B? A systematic review and meta-analysis","volume":"9","author":"Ma","year":"2021","unstructured":"Ma X, Liu S, Wang M, Wang Y, Du S, Xin Y and Xuan S. Tenofovir alafenamide fumarate, tenofovir disoproxil fumarate and entecavir: which is the most effective drug for chronic hepatitis B? A systematic review and meta-analysis. J Clin Transl Hepatol 2021; 9: 335-344.","journal-title":"J Clin Transl Hepatol"}],"container-title":["American Journal of Translational Research"],"original-title":[],"link":[{"URL":"https:\/\/e-century.us\/files\/ajtr\/16\/12\/ajtr0160482.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,18]],"date-time":"2025-12-18T01:55:08Z","timestamp":1766022908000},"score":1,"resource":{"primary":{"URL":"https:\/\/e-century.us\/files\/ajtr\/16\/12\/ajtr0160482.pdf"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024]]},"references-count":27,"journal-issue":{"issue":"12","published-online":{"date-parts":[[2024]]}},"URL":"https:\/\/doi.org\/10.62347\/rknh8649","relation":{},"ISSN":["1943-8141"],"issn-type":[{"value":"1943-8141","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024]]}}}